In a recent study, researchers examined the effectiveness of mRNA vaccines against common cold viruses in immunocompromised adults during two periods when different viruses were predominant. The study found that the vaccines were effective against both viruses, but that they were more effective against the virus that was predominant during the first period.
The study was conducted by researchers at the University of Nebraska Medical Center and was funded by the National Institutes of Health. It was published in the Journal of Infectious Diseases.
In the study, the researchers enrolled immunocompromised adults who were receiving care at the university’s hospital. The participants were divided into two groups: those who received the mRNA vaccine during the first period (BA.4) when the omicron virus was predominant, and those who received the vaccine during the second period (BA.5) when the alpha virus was predominant.
The researchers found that the mRNA vaccine was effective against both viruses. However, they found that the vaccine was more effective against the omicron virus during the first period. The study did not find a statistically significant difference in the effectiveness of the vaccine against the alpha virus between the two periods.
The study’s findings suggest that the mRNA vaccine is effective against common cold viruses, regardless of which virus is predominant. The findings also suggest that the vaccine is more effective against the virus that is predominant during the first period of time after vaccination.
The study’s findings are important because they provide evidence that the mRNA vaccine is effective against common cold viruses in immunocompromised adults. The findings also suggest that the vaccine is more effective when the predominant virus is the omicron virus.
A multistate study has examined the effectiveness of mRNA vaccines for immunocompromised adults during the Omicron BA.4 and BA.5 predominance. The study found that the vaccines are effective in preventing the disease, but that some people may still develop a mild form of the disease. The study also found that the vaccines are safe and well-tolerated by most people.
